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Introduction
Epidemiological studies have suggested that life expectancy
is inversely related to resting heart rate and that the risks of
development of heart failure and sudden cardiac death
strongly increase with higher resting heart rates [1]. After
myocardial infarction, the reduction in mortality with
β-blocker treatment was correlated with the extent of heart
rate reduction, and in patients with heart failure, a drug-
induced increase or decrease in heart rate has been associated
with an increase or decrease in mortality, respectively [2, 3].
The prognostic relevance of heart rate in patients with
coronary artery disease and reduced ejection fraction
recently has been demonstrated in the placebo arm of the
prospective BEAUTIFUL (morBidity-mortality EvAlUaTion
of the If inhibitor ivabradine in patients with coronary
disease and left ventricULar dysfunction) study. The
BEAUTIFUL study included patients with coronary artery
disease and a left ventricular ejection fraction of less than
40%. When patients with heart rates below and above 70
beats per minute were compared, cardiovascular death and
heart failure hospitalization were significantly higher in the
group of patients with higher heart rates [4].
Pathophysiological Considerations
β-Adrenoceptor blocking agents have proven to reduce
mortality and to improve cardiac function in patients with
heart failure and reduced ejection fraction. This beneficial
effect of β-blockers may be partially related to heart rate
reduction, but in addition, protection of the heart and other
organs from catecholamines may contribute significantly
to the effects of these drugs. How could a beneficial effect
of selective heart rate reduction be explained? There are at
least three major aspects to be considered. First, heart rate
is linearly related with myocardial oxygen consumption
[5]. Second, the decrease in heart rate prolongs duration of
diastole, and thereby supports diastolic filling and coro-
nary blood flow. Third, force-frequency relation is
inverted in heart failure: while an increase in heart rate
increases contractile performance in the nonfailing myo-
cardium, higher heart rates are associated with a decline in
contractile function in the failing myocardium. This has
been shown in patient studies as well as in experimental
work in isolated human myocardium [6, 7]. Inverted force-
frequency relation was shown to result from disturbed
calcium cycling at the level of the sarcoplasmic reticulum.
Simply speaking, the higher the heart rate, the shorter the
time available for diastolic calcium accumulation into the
sarcoplasmic reticulum, which, because of disturbed
sarcoplasmic reticulum calcium uptake, results in sarco-
plasmic reticulum calcium depletion with higher heart
rates [8].
SHIFT (Systolic Heart failure treatment with If inhib-
itor ivabradine Trial) investigates the effects of selective
heart rate reduction with ivabradine in patients with heart
failure [9].
Study Design
SHIFT is a randomized, double-blind, placebo-controlled,
parallel-group trial including 6,558 patients who had
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symptomatic heart failure and a left ventricular ejection
fraction below 35%. Patients were randomly assigned to
treatment with ivabradine (3,268 patients) or placebo
(3,290 patients). All patients had to be in sinus rhythm
with a heart rate of at least 70 beats per minute. The
severity of the disease was assured by the inclusion
criterion of heart failure hospitalization within the
previous year. The patients were treated with ivabradine,
5 mg twice daily, or matching placebo. After a period of
14 days, the ivabradine dose was increased to 7.5 mg
twice daily, unless the resting heart rate was below 60
beats per minute. If the heart rate was between 50 and 60
beats per minute, the dose was maintained at 5 mg twice
daily. If resting heart rate was lower than 50 beats per
minute or the patient had signs or symptoms related to
bradycardia, the dose was reduced to 2.5 mg twice daily.
At each follow-up visit, the ivabradine dose was
adjusted. The primary end point was a composite of
cardiovascular death or hospital admission for worsening
heart failure. Secondary end points included heart failure
mortality and hospitalization for heart failure. All of the
events were analyzed on a time-to-first event basis.
Changes in functional capacity were assessed by the
New York Heart Association (NYHA) classification as
well as by patient-reported and physician-reported global
assessments.
Results
The median duration of follow-up was 22.9 months. Heart
rate at inclusion was 79.9±9.6 beats per minute and mean
left ventricular ejection fraction was 29.0%±5.1%. At the
beginning of the trial, mean ivabradine dosage was 6.4±
1.6 mg twice daily, which resulted in a heart rate reduction
of 15.4±10.7 beats per minute. Compared with pretreatment,
when corrected for the change in the placebo group, the net
heart rate reduction with ivabradine was 10.9 beats per
minute. Cardiovascular death or hospital admission for
worsening heart failure occurred in 937 (29%) of the placebo
group versus 793 (24%) of the patients receiving ivabradine
(hazard ratio 0.82; P<0.0001). This indicates that 26 patients
would need treatment for 1 year to prevent one cardiovas-
cular death or one hospital admission for heart failure. The
effect was driven mainly by hospital admissions for
worsening heart failure. From the secondary end points,
death due to heart failure and hospital admission for
worsening heart failure each was reduced by 26%. Subgroup
analysis suggests that the beneficial effect occurs predomi-
nately in patients with high heart rates. There was a small but
significant improvement in the NYHA class. Serious adverse
events were higher in the placebo than in the ivabradine
group. Bradycardia leading to withdrawal from the study
occurred in 1% of patients in the ivabradine group only.
Discussion
Ivabradine acts at the hyperpolarization-activated cyclic
nucleotide-gated channel in the sinoatrial node, thus
inhibiting the specific major pacemaker current (If-funny
current). Because this channel is selectively expressed in
the sinus node, ivabradine does not influence atrioventric-
ular conductance or cardiac performance. Thus, ivabradine
is a selective heart rate-reducing agent. Therefore, SHIFT
clearly shows that selective heart rate reduction in patients
with heart failure and a heart rate above 70 beats per minute
results in significant beneficial effects with respect to
symptoms and prognosis. The patients have been pretreated
according to international guidelines with the following
characteristics: 90% of patients received angiotensin
converting-enzyme inhibitors or angiotensin-receptor
blockers, 90% received β-blockers, and 84% received
diuretics. It also is important to know that 25% of patients
reached the target β-blocker dose and 57% of the patients
reached more than 50% of the target dose. Thus, the patient
cohort represents well-treated patients in the real world.
Quite different from standards in the United States and
Western Europe, the use of devices was rather low (cardiac
resynchronization therapy: 1%; implantable cardioverter-
defibrillator: 4%). This may relate to the fact that a
significant number of patients had been included in
countries with underuse of devices. It also is important to
note that the average age of 60 years was rather young
compared to a typical heart failure population.
Conclusions
SHIFT is an important new drug therapy trial that adds
to the previous successful treatment strategies in patients
with heart failure, including β-adrenoceptor blockers and
renin-angiotensin-aldosterone system antagonists. Be-
cause adverse events of ivabradine treatment are rare
and the beneficial effects of the drugs are impressive, we
should consider treating patients with heart failure with a
resting heart rate above 70 beats per minute with
ivabradine in addition to guideline-recommended heart
failure therapy. Of course, β-blocker treatment should be
uptitrated to a maximum tolerable close, but in daily
practise, because of hypotension and other side effects, a
heart rate below 70 beats per minute is not frequently
achieved with β-blocker treatment in patients with heart
failure. SHIFT nicely fits with pathophysiological con-
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cepts indicating that high heart rate is harmful in patients
with heart failure.
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